---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-054736"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2026-05-12T11:51:50+00:00"
generated_at: "2026-05-12T11:55:24.921409+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Unicycive Q1 2026 net loss $12.8M; OLC PDUFA target June 29, 2026

## Summary
- Net loss of $12.8M ($0.54 per share basic/diluted) vs net income of $0.5M in Q1 2025.
- Cash, cash equivalents & marketable securities $57.1M as of May 11, 2026; funds operations into 2027.
- FDA PDUFA target action date for oxylanthanum carbonate NDA resubmission is June 29, 2026.
- R&D expenses down to $1.6M (from $2.2M); G&A up to $6.8M (from $5.8M) year-over-year.
- Commercial readiness activities ongoing for potential OLC launch after PDUFA.

## SEC filing metadata
- accession: 0001213900-26-054736
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2026-05-12T11:51:50+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/0001213900-26-054736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/ea0290277-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-054736
- JSON: https://secwatch.observer/filing/0001213900-26-054736.json
- Plain text: https://secwatch.observer/filing/0001213900-26-054736.txt

## Key facts
- Earnings Releases
  Unicycive Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $(12.8) million loss, EPS $(0.54) per share of common stock.
  - Period: the first quarter ended March 31, 2026
  - Net income: $(12.8) million loss
  - EPS: $(0.54) per share of common stock
  - Result: reported results
  source text: Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/0001213900-26-054736-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.